NZ591387A - N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b - Google Patents

N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b

Info

Publication number
NZ591387A
NZ591387A NZ591387A NZ59138709A NZ591387A NZ 591387 A NZ591387 A NZ 591387A NZ 591387 A NZ591387 A NZ 591387A NZ 59138709 A NZ59138709 A NZ 59138709A NZ 591387 A NZ591387 A NZ 591387A
Authority
NZ
New Zealand
Prior art keywords
pyridine
aminophenyl
benzamide
polymorph
methoxycarbonylaminomethyl
Prior art date
Application number
NZ591387A
Other languages
English (en)
Inventor
Matthias Schneider
Michael Gottfried
Jens Geisler
Gabriele Winter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ591387(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NZ591387A publication Critical patent/NZ591387A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ591387A 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b NZ591387A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29
PCT/EP2009/006381 WO2010022988A1 (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b

Publications (1)

Publication Number Publication Date
NZ591387A true NZ591387A (en) 2012-03-30

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ591387A NZ591387A (en) 2008-08-29 2009-08-27 N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275) polymorph b

Country Status (35)

Country Link
US (2) US7973166B2 (enExample)
EP (1) EP2350005B1 (enExample)
JP (1) JP4921616B2 (enExample)
KR (1) KR101073760B1 (enExample)
CN (1) CN102137846B (enExample)
AR (1) AR073226A1 (enExample)
AT (1) ATE538094T1 (enExample)
AU (1) AU2009286982C1 (enExample)
BR (1) BRPI0918580B8 (enExample)
CA (1) CA2735294C (enExample)
CO (1) CO6351736A2 (enExample)
CR (2) CR20110107A (enExample)
CY (1) CY1112645T1 (enExample)
DK (1) DK2350005T3 (enExample)
DO (1) DOP2011000064A (enExample)
EA (1) EA016811B1 (enExample)
EC (1) ECSP11010849A (enExample)
ES (1) ES2378640T3 (enExample)
HN (1) HN2011000609A (enExample)
HR (1) HRP20120183T8 (enExample)
IL (1) IL211276A (enExample)
MA (1) MA32610B1 (enExample)
MX (1) MX2011002248A (enExample)
MY (1) MY149058A (enExample)
NZ (1) NZ591387A (enExample)
PE (2) PE20110677A1 (enExample)
PL (1) PL2350005T3 (enExample)
PT (1) PT2350005E (enExample)
RS (1) RS52164B (enExample)
SI (1) SI2350005T1 (enExample)
SM (1) SMT201200026B (enExample)
SV (1) SV2011003846A (enExample)
TW (1) TWI427062B (enExample)
WO (1) WO2010022988A1 (enExample)
ZA (1) ZA201102285B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52164B (sr) 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
CN110944978A (zh) * 2017-07-28 2020-03-31 杭州领业医药科技有限公司 含恩替诺特的化合物,其化合物晶型及其制备方法和药物组合物
CA3218617A1 (en) 2021-05-10 2022-11-17 Thierry Bonnaud Novel forms of entinostat

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
RS52164B (sr) 2008-08-29 2012-08-31 Bayer Pharma Aktiengesellschaft N-(2-aminofenil)-4-[n-(piridin-3-il)-metoksikarbonilaminometil]-benzamid (ms-275)polimorf b

Also Published As

Publication number Publication date
CY1112645T1 (el) 2016-02-10
EP2350005B1 (en) 2011-12-21
SV2011003846A (es) 2011-07-27
DK2350005T3 (da) 2012-03-19
CN102137846B (zh) 2014-04-23
ZA201102285B (en) 2011-12-28
KR101073760B1 (ko) 2011-10-13
JP4921616B2 (ja) 2012-04-25
US20100056585A1 (en) 2010-03-04
PE20141062A1 (es) 2014-09-19
KR20110038187A (ko) 2011-04-13
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
MX2011002248A (es) 2011-03-29
HRP20120183T1 (hr) 2012-03-31
TWI427062B (zh) 2014-02-21
ECSP11010849A (es) 2011-03-31
HRP20120183T8 (en) 2012-11-30
CR20110107A (es) 2011-04-28
CA2735294A1 (en) 2010-03-04
EP2350005A1 (en) 2011-08-03
RS52164B (sr) 2012-08-31
PT2350005E (pt) 2012-03-12
PL2350005T3 (pl) 2012-05-31
US7973166B2 (en) 2011-07-05
CA2735294C (en) 2013-10-15
SI2350005T1 (sl) 2012-03-30
JP2012500819A (ja) 2012-01-12
SMT201200026B (it) 2012-07-10
AU2009286982B2 (en) 2011-06-23
USRE45499E1 (en) 2015-04-28
HK1160107A1 (en) 2012-08-10
CO6351736A2 (es) 2011-12-20
AR073226A1 (es) 2010-10-20
ES2378640T3 (es) 2012-04-16
WO2010022988A1 (en) 2010-03-04
CR20160465A (es) 2016-12-06
AU2009286982A1 (en) 2010-03-04
MA32610B1 (fr) 2011-09-01
IL211276A (en) 2014-07-31
DOP2011000064A (es) 2011-03-31
BRPI0918580B1 (pt) 2020-11-24
IL211276A0 (en) 2011-04-28
HN2011000609A (es) 2014-09-29
BRPI0918580A8 (pt) 2017-07-11
CN102137846A (zh) 2011-07-27
AU2009286982C1 (en) 2012-04-26
EA016811B1 (ru) 2012-07-30
ATE538094T1 (de) 2012-01-15
EA201100354A1 (ru) 2011-10-31
TW201014820A (en) 2010-04-16
BRPI0918580B8 (pt) 2021-05-25
BRPI0918580A2 (pt) 2015-12-01

Similar Documents

Publication Publication Date Title
USRE45499E1 (en) N-(2-aminophenyl)-4-[N-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B
US10383876B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
CN102762557B (zh) 三唑并吡啶
CN102753547B (zh) 三唑并吡啶衍生物
US9381177B2 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CA2902978A1 (en) Substituted imidazopyridazines
GB2462893A (en) Preparation of and compositions comprising N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylaminomethyl]-benzamide (MS-275) polymorph B
HK1160107B (en) N-(2-aminophenyl)-4-[n-(pyridine-3-yl)-methoxycarbonyl-aminomethyl]-benzamide (ms-275)polymorph b
NZ616198B2 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 AUG 2016 BY CPA GLOBAL

Effective date: 20130718

ASS Change of ownership

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Effective date: 20130822

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2017 BY CPA GLOBAL

Effective date: 20160722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2018 BY CPA GLOBAL

Effective date: 20170720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2019 BY CPA GLOBAL

Effective date: 20180719

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2020 BY CPA GLOBAL

Effective date: 20190718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2021 BY CPA GLOBAL

Effective date: 20200716

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2022 BY CPA GLOBAL

Effective date: 20210722

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2023 BY CPA GLOBAL

Effective date: 20220721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2024 BY CPA GLOBAL

Effective date: 20230720

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240718

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 AUG 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250717